
==== Front
J Bone Miner Metab
J Bone Miner Metab
Journal of Bone and Mineral Metabolism
0914-8779
1435-5604
Springer Nature Singapore Singapore

38856919
1520
10.1007/s00774-024-01520-8
Invited Review
Inflammatory diseases causing joint and bone destruction: rheumatoid arthritis and hemophilic arthropathy
http://orcid.org/0000-0001-5150-5656
Terashima Asuka 1
Ono Kumiko 23
Omata Yasunori 13
Tanaka Sakae 3
http://orcid.org/0000-0003-4911-3930
Saito Taku tasaitou-tky@umin.ac.jp

3
1 grid.412708.8 0000 0004 1764 7572 Bone and Cartilage Regenerative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-8655 Japan
2 grid.26999.3d 0000 0001 2151 536X Department of Joint Surgery, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo 108-8639 Japan
3 https://ror.org/057zh3y96 grid.26999.3d 0000 0001 2169 1048 Orthopaedic Surgery, Sensory and Motor System Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-8655 Japan
10 6 2024
10 6 2024
2024
42 4 455462
13 11 2023
20 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Various diseases and conditions cause joint disorders. Osteoarthritis (OA) is characterized by the degeneration of articular cartilage, synovitis, and anabolic changes in surrounding bone tissues. In contrast, rheumatoid arthritis (RA) and hemophilic arthropathy (HA) display marked destruction of bone tissues caused by synovitis. RA is a representative autoimmune disease. The primary tissue of RA pathogenesis is the synovial membrane and involves various immune cells that produce catabolic cytokines and enzymes. Hemophilia is a genetic disorder caused by a deficiency in blood clotting factors. Recurrent intra-articular bleeding leads to chronic synovitis through excessive iron deposition and results in the destruction of affected joints. Although the triggers for these two joint diseases are completely different, many cytokines and enzymes are common in the pathogenesis of both RA and HA. This review focuses on the similarities between joint and bone destruction in RA and HA. The insights may be useful in developing better treatments for hemophilia patients with arthropathy and osteoporosis by leveraging advanced therapeutics for RA.

Keywords

Rheumatoid arthritis
Hemophilia
Hemophilic arthropathy
Joint destruction
http://dx.doi.org/10.13039/501100001691 Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) Terashima Asuka The University of TokyoOpen Access funding provided by The University of Tokyo.

issue-copyright-statement© The Japanese Society for Bone and Mineral Research 2024
==== Body
pmcIntroduction

Various conditions or diseases can impair the function of articular joints, and subsequent joint pain restricts the activity of daily living. The most prevalent joint disorder is osteoarthritis (OA), a degenerative condition caused by aging, obesity, overuse, joint instability, or other factors. In most of OA joints, articular cartilage is degenerated, and symptoms and disease progression are associated with inflammation of the synovial membrane, known as synovitis. In contrast to cartilage, anabolic changes are commonly observed in bone tissues surrounding the affected joints, e.g., osteophyte formation and subchondral bone sclerosis.

Joints are also affected by autoimmune disorder, such as rheumatoid arthritis (RA), systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, and scleroderma. Among them, RA is the most prevalent and has been well researched for decades. The pathogenesis of RA is determined by multiple factors, including genetic and environmental backgrounds. The primary tissue of the RA pathogenesis is the synovial membrane. Autoantibodies, such as rheumatoid factor and anti-citrullinated protein antibodies, are often observed in patients with RA. T cells and B cells play crucial roles in the inflammatory response [1]. Chronic synovitis leads to the release of cytokines, such as tumor necrosis factor (TNF) and interleukins (IL), along with other inflammatory mediators [1]. These cytokines further exacerbate synovitis, resulting in the destruction of cartilage and bone. In contrast to anabolic changes of bone tissues of joints with OA, both articular cartilage and bone tissues are usually destructed in RA if not appropriately treated.

The destruction of cartilage and bone following synovitis is also observed in patients with hemophilia. Hemophilia is a rare genetic disorder caused by a deficiency in certain blood clotting factors, particularly Factor VIII (in hemophilia A) or Factor IX (in hemophilia B). These factors are crucial for effective blood clotting in response to injury. Recurrent bleeding into synovial joints destroys articular cartilage and bone tissues, i.e., hemophilic arthropathy (HA). Synovitis plays a pivotal role in HA, as well as in RA. Blood within the joint space triggers inflammatory responses in the synovium, further damaging the articular cartilage and bone tissues [2]. Of note, many aspects of the pathophysiology of HA retain unelucidated since the molecular mechanisms of HA have not been studied as extensively as those of RA. In this review, we describe the similarities and differences in joint and bone destruction between RA and HA, which may contribute to providing better methods for maintaining physical activity in patients with hemophilia by leveraging advanced therapeutics for RA.

Epidemiology and phenotypes

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by severe joint destruction with inflammatory synovitis. The estimated global prevalence of RA is 0.5–1.0%, with geographical differences [1]. The prevalence of RA in Western countries is higher than in Asia [1, 3]. There are an estimated 800,000 RA patients in Japan, with a male-to-female ratio of approximately 1:3 [4]. The prevalence of RA increased with age, typically after 30 years, and onset age peaks in the late 60s [5]. Recently, the number of people developing RA at even older ages has been increasing in Japan. In the older patients, the gender difference in prevalence decreases, with a male–female ratio is 1:2 to 3 [5]. RA patients display pain, stiffness, and swelling of multiple joints caused by synovitis. RA typically manifests symmetrically in the metacarpophalangeal and proximal interphalangeal joints of hands and feet, as well as in the wrist, shoulder, hip, knee, and ankle joints [1], but onset patterns are diverse. Formerly, chronic inflammation led to the destruction of articular cartilage and surrounding bone tissues, resulting in serious joint deformity over time. The elucidation of RA pathophysiology has contributed to the development of effective drug treatments, including methotrexate, biological drugs, and Janus kinase (JAK) inhibitors. These latest therapeutics have markedly improved the prognosis of RA patients, although treatment remains challenging for some sub-population of the patients.

Hemophilia is usually inherited via X chromosome with a mutation of the FVIII or FIX gene [6]. However, both genes are prone to new mutations, and about 30% of all cases result from spontaneous genetic variants, without family history of the disease [6]. Because hemophilia is X-linked, more than 98% of patients with hemophilia are male in Japan [7]. In the United States, the male incidence of hemophilia A and hemophilia B at birth is about 1 per 5000 and 1 per 30,000, respectively [8]. According to a report in 2022, there are 5776 hemophilia A patients and 1294 hemophilia B patients in Japan [7]. The affected neonates and infants often experience spontaneous hemorrhage, such as abnormal bleeding after blood draws, surgery, or trauma, subcutaneous bleeding, and intracranial hemorrhage [8]. The incidence of intra-articular bleeding increases as the patients grow up, and that of joint pain increases in their teens. The intra-articular bleeding typically occurs in the knee, ankle, and elbow [8]. More than half of hemophilia patients find it difficult to squat by the time they reach their 30s, and over 80% of patients aged 60 or older experience some form of joint dysfunction. Therefore, the onset of HA is earlier than that of RA. The development of blood clotting factor products has significantly improved hemostatic control in hemophilia patients. However, the occurrence and progression of HA cannot be completely prevented or inhibited even by these drugs. A magnetic resonance imaging study showed that joint damage was identified in approximately 20% of clinically asymptomatic patients with HA, despite receiving prophylaxis [9].

Genetic backgrounds

In accordance with the former epidemiologic studies indicating a genetic component in RA, genome-wide association studies have identified at least 100 susceptibility loci for RA [10–13]. These loci are enriched for immune or inflammation-related genes [12]. Certain genes, such as HLA-DR4, HLA-DR1, and HLA-DRB1, have been associated with an increased risk of RA [1]. There is a range of other susceptibility genes for RA: protein tyrosine phosphatase non-receptor type 22 (PTPN22) is involved in regulating immune responses [12, 14]; tumor necrosis factor alpha-induced protein 3 (TNFAIP3) is a regulator of inflammation [15–17]; C–C chemokine receptor type 6 (CCR6) is responsible for the recruitment of immune cells to inflamed tissues [18]; CCR6-expressing Th17 cells are potent inducers of inflammation (they can migrate to the inflamed synovium under the guidance of chemokines, including CCL20, which binds to CCR6 [19]); the interferon regulatory factor 5 (IRF5) gene (coding an immune response-related protein) is also associated with other autoimmune diseases, as well as RA [20, 21]. The diversity in genetic backgrounds as described above might be linked to the diversity in the phenotype of RA.

On the other hand, hemophilia is a typical monogenic disorder. Although the severity of hemophilia depends on the type of genetic mutation [22], the genetic factors for HA are much less diverse than those for RA. Genetic studies for hemophilia have mainly focused on the emergence of inhibitors against infused clotting factor concentrates, which make managing hemophilia more difficult [23]. Rather than genetic factors, the amount and mode of exercise, lifestyle factors, and medication compliance may be more deeply involved in the occurrence or progression of HA [24, 25].

Cytokines and synovitis

The development of effective RA treatments can be attributed to identifying cytokines, their related signaling pathways, and responsible immune cells that contribute to synovitis and produce the cytokines [1]. Among the various cytokines, IL-6, IL-1β, and TNF play pivotal roles. They are deeply involved in inflammatory pathways, particularly the nuclear factor kappa B (NF-κB) and the JAK-signal transducer and activator of transcription 3 (STAT3) pathways. NF-κB is widely associated with acute and chronic inflammatory responses. IL-1β and TNF are representative cytokines that activate NF-κB, which upregulates IL-1β, TNF, and IL-6 [26]. IL-6 activates the JAK-STAT3 pathway, exerting various effects. IL-6 is also a downstream molecule of the JAK-STAT3 pathway. The feedback loops of these cytokines and pathways enhance inflammation in RA [26]. The JAK-STAT3 and NF-κB signaling pathways interact with each other and work collaboratively through IL-6 and other cytokines [26].

Various cells produce IL-6, including macrophages, T cells, endothelial cells and fibroblast-like synoviocytes (FLS) in the RA synovium, and it contributes to sustained synovitis through the signaling pathways described above. The significance of IL-6 is clearly displayed by previous findings that IL-6-deficient mice display little or no antigen-induced arthritis [27]. Indeed, the antibody against IL-6 has shown efficacy in treating RA patients [28]. TNF is another therapeutic target in RA. TNF is produced by macrophages, T cells, and FLS [27, 29]. TNF can boost NF-κB and further enhance IL-6 production. TNF signaling plays a predominant role in establishing an experimental model of RA [30]. TNF inhibitors have also been widely used for treating RA patients with high efficacy [31]. In addition, IL-17 and IL-23 are associated with RA pathogenesis [27]. IL-17 is predominantly secreted by Th17 cells, and IL-23 contributes to the differentiation and maintenance of Th17 cells.

The trigger for HA is intra-articular bleeding. Intra-articular bleeding causes iron deposition in the synovium as a product of hemoglobin degradation [32]. The monocytes/macrophages can phagocytose red blood cells and process the iron from hemoglobin [32]. Recurrent bleeding and excessive iron deposition subsequently enhance catabolic cytokines and enzymes, which could lead to the destruction of articular cartilage and bone tissues [32]. Hemoglobin-derived iron can act as a catalyst for the Fenton reaction in which hydroxyl radicals are formed from hydrogen peroxide, and may directly damage to chondrocytes [33].

Some cytokines in HA are common to RA. In hemophilic arthritis mice, bleeding into the joints can trigger the release of IL-1β, IL-6, C-X-C motif chemokine ligand 1 (CXCL1) and CCL2, contributing to joint inflammation and pain [34]. These cytokines have also been observed in patients with RA [35, 36]. The production of IL-6 was significantly higher in HA synovium than in RA or OA synovium in vitro [37]. Anti IL-6 receptor antibody improved acute joint swelling and pathologic changes in the synovium and cartilage of the experimental model of HA [38]. Blood components elicit the production and release of TNF from macrophages in vitro [39, 40]. TNF expression increased in the soft tissue of mice joints after injury [41] and in the synovial fluid of patients suffering from hemarthrosis caused by an ACL injury [42]. In addition, the activation of osteoclasts and the resulting osteopenia in the trabecular bone adjacent to the hemarthrosis were prevented in TNF-deficient mice [41]. In HA patients, anti-TNF therapy decreased synovitis and hemarthroses [43]. IL-1β is also released in response to joint bleeding. It promotes inflammation, cartilage degradation, and the recruitment of immune cells to the affected joint. IL-1β has been investigated as a potential therapeutic target in HA [44].

Catabolic enzymes

Matrix metalloproteinases (MMPs) are enzymes that can be produced in response to inflammation and are involved in cartilage degradation. In healthy conditions, MMPs could help to maintain tissue homeostasis by breaking down and remodeling components of the extracellular matrix [45]. This process may be essential for normal tissue repair and turnover. However, in arthritis, MMPs are often overproduced and cause excessive tissue remodeling or damage [35]. They break down the structural proteins within cartilage, such as collagen and proteoglycans, leading to cartilage erosion and bone loss. Furthermore, MMPs could have not only a degradative function in cartilage but also a pro-inflammatory effect [35]. They have the ability to cleave and activate pro-inflammatory cytokines, such as pro-IL-1 and the latent type of transforming growth factor-β (TGF-β) [46, 47]. Although TGF-β is essential for tissue repair, TGF-β is a potent osteoclastogenesis inducer [27].

MMPs are found in the joint fluid of patients with RA and HA [1, 48]. There are more than 20 members of the MMP family. MMP-1 levels are elevated in various arthritic conditions [49, 50]. MMP-3 is one of the most extensively studied MMPs in RA [51]. Elevated levels of serum MMP-3 are associated with synovial inflammation and joint destruction in RA [52]. It can be measured in the synovial fluid of RA patients [52, 53]. MMP-1, -2, and -3 are detected in ligaments of patients with HA more abundantly than in those tissues of OA patients [48]. Like RA, the MMPs are expected to enhance joint destruction in HA. MMP-13, which is involved in the degradation of type II collagen, has also been explored in RA [54]. Joint bleeding in rats significantly increased the expression of MMP-13, compared with a control group [55]. Furthermore, elevated MMP-13 expression has been observed in knee joint punctured-F8 knockout mice, which mimic hemophilia A [56].

Bone destruction and systemic decreases in bone mineral density in RA and HA

A key phenomenon common in RA and HA is bone erosion subsequent to synovitis. This requires activation of osteoclasts, the only cells that resorb bone. Important insights into the role of osteoclasts in the pathogenesis of bone erosion around the periarticular lesions were provided by examining experimental arthritis in osteoclast-deficient mice. The receptor activator of NF-kB ligand (RANKL) is a key cytokine that is indispensable for osteoclastogenesis. RANKL knockout mice, which lack the capacity to form osteoclasts, failed to develop significant bone erosions in arthritis models [27]. Moreover, knockout mice of c-fos, an essential transcription factor for osteoclastogenesis, cannot generate osteoclasts [57]. When the c-fos−/− mice were backcrossed with TNF transgenic mice which spontaneously develop arthritis, bone erosion was not observed despite comparable joint inflammation to their wild-type littermates [58]. These findings provide definitive evidence that osteoclasts are essential for bone destruction in arthritis.

Notably, the cytokines responsible for RA pathogenesis positively regulate osteoclast formation by increasing RANKL expression in osteoclast-supporting mesenchymal cells [27]. RANKL is induced by IL-6 stimulation in FLS from RA patients, and the IL-6 production is elicited by TNF, IL-1β, and IL-17 [59]. High expression of RANK and RANKL has also been detected in the HA synovium, suggesting osteoclastogenesis is activated in HA [60]. There was no significant difference in osteoclast numbers in the subchondral bone of femoral heads between HA and RA groups [61], nor were there significant differences in the expression of RANKL, RANK, TNF, and IL-1β in femoral heads derived from HA and RA patients [61]. To promote a better understanding of the similarities and differences between RA and HA described above, an outline of this review is illustrated in Table 1 and Fig. 1.Table 1 Comparison between rheumatoid arthritis (RA) and hemophilic arthropathy (HA)

	Rheumatoid arthritis (RA)	Hemophilic arthropathy (HA)	Reference	
Estimated number of patients in Japan	Estimated 800,000	Estimated 5000	[1], [7]	
Male-to-female ratio	1:3	The majority are male. (Since hemophilia is an X-linked disease, the ratio is unbalanced.)	[4], [7]	
Typical age of joint pain onset	Late 60s	Under 30s	[5], [8]	
Affected joints	Symmetric arthritis in various joints	Mainly in the elbow, knee, and ankle joints	[1], [8]	
Causes	Autoimmune disorder	Intra-articular bleeding caused by coagulation disorders	[1], [8]	
Highly associated cytokines	TNF, IL-6, IL-1b, IL-17, IL-23, etc.	IL-6, TNF	[27–31], [38–40]	
Highly associated genes	HLA-DRB1, PTPN22, TNFAIP3, TNFAIP3, CCR6, IRF5, etc.	Blood clotting factors (F8, F9, etc.)	[12], [14–21]	
RA and HA have similarities and differences. It is thought that the large differences in the causes affect the onset age and site. Similarities can be seen in inflammatory cytokines

Fig. 1 Joint destruction in rheumatoid arthritis (RA) and hemophilic arthropathy (HA). This figure shows the main causes of each pathological condition and the cells and cytokines affected within the joint. This figure shows the main causes of each pathological condition and the cells and cytokines affected within the joint

Systemic decreases in bone mineral density (BMD), as in osteopenia and osteoporosis, are common in both RA and HA patients, along with periarticular bone destruction. Bone absorption is frequently enhanced in both patient groups [62, 63]. Previous studies suggest that similar pathogenic factors, such as RANKL and inflammatory cytokines mentioned above, are involved in osteoclastogenesis upregulation [62, 63]. The decreased physical activity caused by joint pain and subsequent vitamin D deficiency also reduces BMD in these patients [62, 63]. Glucocorticoids, which have been widely used for treating RA, further exacerbate osteopenia or osteoporosis and increase the risk of fracture [62]. Many studies have shown the efficacy of anti-resorptive agents such as bisphosphonate and denosumab for RA-associated or glucocorticoid-induced osteoporosis [62]. In contrast, there has only been one clinical trial for managing low BMD in patients with hemophilia, indicating the efficacy of ibandronate [63, 64]. Considering the similar pathogenesis underlying systemic decreases in BMD, efficient regulation of disease activity contributes to preventing osteopenia or osteoporosis in both groups of patients. Appropriate medication for osteoporosis should be considered when the risk of fracture rises.

Conclusion

Although the triggers are quite different, the inflammatory cytokines and some secreted proteins involved in the synovitis are similar between RA and HA. Enhanced bone resorption caused by excessive osteoclastogenesis is also similar in both conditions. Denosumab, anti-RANKL antibody drug, is effective not only for osteoporosis but also for bone erosion in RA joints [65]. Considering the similarities in bone destruction between RA and HA, anti-bone resorptive agents or biologic drugs against IL-6 or TNF may demonstrate efficacy against HA as well as RA. Meanwhile, unlike RA, HA typically occurs early in life, sometimes in childhood. To overcome HA, further research is required to elucidate the underlying molecular mechanisms, which may, in turn, contribute to improving the management of joint disorders, including OA, RA, and HA.

Author contributions

ST and TS provided the idea for the article; AT, KO, YO, and TS performed the literature search; all the authors drafted or revised the manuscript.

Funding

Open Access funding provided by The University of Tokyo. Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Asuka Terashima.

Declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Smolen JS Aletaha D Barton A Burmester GR Emery P Firestein GS Kavanaugh A McInnes IB Solomon DH Strand V Yamamoto K Rheumatoid arthritis Nat Rev Dis Primers 2018 4 18001 10.1038/nrdp.2018.1 29417936
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. 10.1038/nrdp.2018.129417936
2. Valentino L Blood-induced joint disease: the pathophysiology of hemophilic arthropathy J Thromb Haemost 2010 8 1895 1902 10.1111/j.1538-7836.2010.03962.x 20586922
Valentino L (2010) Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 8:1895–190220586922
3. Safiri S Kolahi AA Hoy D Smith E Bettampadi D Mansournia MA Almasi-Hashiani A Ashrafi-Asgarabad A Moradi-Lakeh M Qorbani M Collins G Woolf AD March L Cross M Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017 Ann Rheum Dis 2019 78 1463 1471 10.1136/annrheumdis-2019-215920 31511227
Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, Almasi-Hashiani A, Ashrafi-Asgarabad A, Moradi-Lakeh M, Qorbani M, Collins G, Woolf AD, March L, Cross M (2019) Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis 78:1463–1471. 10.1136/annrheumdis-2019-21592031511227
4. Nakajima A Sakai R Inoue E Harigai M Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the national database of health insurance claims and specific health checkups of Japan Int J Rheum Dis 2020 23 1676 1684 10.1111/1756-185X.13974 33016574
Nakajima A, Sakai R, Inoue E, Harigai M (2020) Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the national database of health insurance claims and specific health checkups of Japan. Int J Rheum Dis 23:1676–168433016574
5. Kojima M Nakayama T Tsutani K Igarashi A Kojima T Suzuki S Miyasaka N Yamanaka H Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey Mod Rheumatol 2020 30 941 947 10.1080/14397595.2019.1682776 31625435
Kojima M, Nakayama T, Tsutani K, Igarashi A, Kojima T, Suzuki S, Miyasaka N, Yamanaka H (2020) Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol 30:941–947. 10.1080/14397595.2019.168277631625435
6. Calvez T Chambost H Claeyssens-Donadel S d'Oiron R Goulet V Guillet B Héritier V Milien V Rothschild C Roussel-Robert V Vinciguerra C Goudemand J Network F Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A Blood 2014 124 3398 3408 10.1182/blood-2014-07-586347 25253771
Calvez T, Chambost H, Claeyssens-Donadel S, d’Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J, Network F (2014) Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124:3398–3408. 10.1182/blood-2014-07-58634725253771
7. Nationwide Survey on Coagulation Disorders 2022 (2022) Japan Foundation for AIDS Prevention
8. Kulkarni R Soucie JM Pediatric hemophilia: a review Semin Thromb Hemost 2011 37 737 744 10.1055/s-0031-1297164 22187396
Kulkarni R, Soucie JM (2011) Pediatric hemophilia: a review. Semin Thromb Hemost 37:737–744. 10.1055/s-0031-129716422187396
9. Manco-Johnson MJ, Soucie JM, Gill JC, Joint Outcomes Committee of the Universal Data Collection USHTCN Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project Blood 2017 129 2368 2374 10.1182/blood-2016-02-683169 28183693
Manco-Johnson MJ, Soucie JM, Gill JC, Joint Outcomes Committee of the Universal Data Collection USHTCN (2017) Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood 129:2368–2374. 10.1182/blood-2016-02-68316928183693
10. Stahl EA Raychaudhuri S Remmers EF Xie G Eyre S Thomson BP Li Y Kurreeman FA Zhernakova A Hinks A Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci Nat Genet 2010 42 508 514 10.1038/ng.582 20453842
Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–51420453842
11. Okada Y Terao C Ikari K Kochi Y Ohmura K Suzuki A Kawaguchi T Stahl EA Kurreeman FA Nishida N Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population Nat Genet 2012 44 511 516 10.1038/ng.2231 22446963
Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Kawaguchi T, Stahl EA, Kurreeman FA, Nishida N (2012) Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 44:511–51622446963
12. Okada Y Wu D Trynka G Raj T Terao C Ikari K Kochi Y Ohmura K Suzuki A Yoshida S Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature 2014 506 376 381 10.1038/nature12873 24390342
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376–38124390342
13. Eyre S Bowes J Diogo D Lee A Barton A Martin P Zhernakova A Stahl E Viatte S McAllister K High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis Nat Genet 2012 44 1336 1340 10.1038/ng.2462 23143596
Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K (2012) High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44:1336–134023143596
14. Begovich AB Carlton VE Honigberg LA Schrodi SJ Chokkalingam AP Alexander HC Ardlie KG Huang Q Smith AM Spoerke JM A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis Am J Hum Genet 2004 75 330 337 10.1086/422827 15208781
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:330–33715208781
15. Elsby LM Orozco G Denton J Worthington J Ray DW Donn RP Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis Clin Exp Rheumatol 2010 28 708 20822710
Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP (2010) Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 28:70820822710
16. Dieguez-Gonzalez R Calaza M Perez-Pampin E Balsa A Blanco FJ Cañete JD Caliz R Carreño L de la Serna AR Fernandez-Gutierrez B Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility Arthritis Res Ther 2009 11 1 8 10.1186/ar2650
Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, Balsa A, Blanco FJ, Cañete JD, Caliz R, Carreño L, de la Serna AR, Fernandez-Gutierrez B (2009) Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther 11:1–8
17. Matmati M Jacques P Maelfait J Verheugen E Kool M Sze M Geboes L Louagie E Guire CM Vereecke L A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis Nat Genet 2011 43 908 912 10.1038/ng.874 21841782
Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, Geboes L, Louagie E, Guire CM, Vereecke L (2011) A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 43:908–91221841782
18. Kochi Y Okada Y Suzuki A Ikari K Terao C Takahashi A Yamazaki K Hosono N Myouzen K Tsunoda T A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility Nat Genet 2010 42 515 519 10.1038/ng.583 20453841
Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, Yamazaki K, Hosono N, Myouzen K, Tsunoda T (2010) A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42:515–51920453841
19. Hirota K Yoshitomi H Hashimoto M Maeda S Teradaira S Sugimoto N Yamaguchi T Nomura T Ito H Nakamura T Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model J Exp Med 2007 204 2803 2812 10.1084/jem.20071397 18025126
Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204:2803–281218025126
20. Shimane K Kochi Y Yamada R Okada Y Suzuki A Miyatake A Kubo M Nakamura Y Yamamoto K A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population Ann Rheum Dis 2009 68 377 383 10.1136/ard.2007.085704 18408250
Shimane K, Kochi Y, Yamada R, Okada Y, Suzuki A, Miyatake A, Kubo M, Nakamura Y, Yamamoto K (2009) A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. Ann Rheum Dis 68:377–38318408250
21. Maalej A Hamad MB Rebai A Teixeira VH Bahloul Z Marzouk S Farid NR Ayadi H Cornélis F Petit-Teixeira E Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population Scand J Rheumatol 2008 37 414 418 10.1080/03009740802256327 18752149
Maalej A, Hamad MB, Rebai A, Teixeira VH, Bahloul Z, Marzouk S, Farid NR, Ayadi H, Cornélis F, Petit-Teixeira E (2008) Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population. Scand J Rheumatol 37:414–41818752149
22. Castaman G Matino D Hemophilia A and B: molecular and clinical similarities and differences Haematologica 2019 104 1702 1709 10.3324/haematol.2019.221093 31399527
Castaman G, Matino D (2019) Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 104:1702–1709. 10.3324/haematol.2019.22109331399527
23. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert A-K, Group MS Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A Blood 2006 108 3739 3745 10.1182/blood-2006-05-024711 16926287
Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert A-K, Group MS (2006) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108:3739–374516926287
24. Cuesta-Barriuso R Donoso-Úbeda E Meroño-Gallut J Ucero-Lozano R Pérez-Llanes R Hemophilic arthropathy: barriers to early diagnosis and management J Blood Med 2022 13 589 601 10.2147/JBM.S343924 36277171
Cuesta-Barriuso R, Donoso-Úbeda E, Meroño-Gallut J, Ucero-Lozano R, Pérez-Llanes R (2022) Hemophilic arthropathy: barriers to early diagnosis and management. J Blood Med 13:589–601. 10.2147/JBM.S34392436277171
25. Torres-Ortuño A Cuesta-Barriuso R Nieto-Munuera J Galindo-Piñana P López-Pina JA The behaviour and perception of illness: modulating variables of adherence in patients with haemophilia Vox Sang 2018 10.1111/vox.12669 29797724
Torres-Ortuño A, Cuesta-Barriuso R, Nieto-Munuera J, Galindo-Piñana P, López-Pina JA (2018) The behaviour and perception of illness: modulating variables of adherence in patients with haemophilia. Vox Sang. 10.1111/vox.1266929797724
26. Ibrahim SSA Huttunen KM Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways Inflammopharmacology 2021 29 965 974 10.1007/s10787-021-00800-3 33740220
Ibrahim SSA, Huttunen KM (2021) Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways. Inflammopharmacology 29:965–974. 10.1007/s10787-021-00800-333740220
27. Okamoto K Nakashima T Shinohara M Negishi-Koga T Komatsu N Terashima A Sawa S Nitta T Takayanagi H Osteoimmunology: the conceptual framework unifying the immune and skeletal systems Physiol Rev 2017 97 1295 1349 10.1152/physrev.00036.2016 28814613
Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A, Sawa S, Nitta T, Takayanagi H (2017) Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev 97:1295–1349. 10.1152/physrev.00036.201628814613
28. Narazaki M Tanaka T Kishimoto T The role and therapeutic targeting of IL-6 in rheumatoid arthritis Expert Rev Clin Immunol 2017 13 535 551 10.1080/1744666X.2017.1295850 28494214
Narazaki M, Tanaka T, Kishimoto T (2017) The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol 13:535–55128494214
29. Steiner G Tohidast-Akrad M Witzmann G Vesely M Studnicka-Benke A Gal A Kunaver M Zenz P Smolen J Cytokine production by synovial T cells in rheumatoid arthritis Rheumatology (Oxford) 1999 38 202 213 10.1093/rheumatology/38.3.202 10325658
Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen J (1999) Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38:202–21310325658
30. Mori L Iselin S De Libero G Lesslauer W Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice J Immunol (Baltimore, Md: 1950) 1996 157 3178 3182 10.4049/jimmunol.157.7.3178
Mori L, Iselin S, De Libero G, Lesslauer W (1996) Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol (Baltimore, Md: 1950) 157:3178–3182
31. Tanaka S Tanaka Y Ishiguro N Yamanaka H Takeuchi T RANKL: a therapeutic target for bone destruction in rheumatoid arthritis Mod Rheumatol 2018 28 9 16 10.1080/14397595.2017.1369491 28880683
Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T (2018) RANKL: a therapeutic target for bone destruction in rheumatoid arthritis. Mod Rheumatol 28:9–1628880683
32. Roosendaal G Lafeber FP Pathogenesis of haemophilic arthropathy (in eng) Haemophilia 2006 12 117 121 10.1111/j.1365-2516.2006.01268.x 16684006
Roosendaal G, Lafeber FP (2006) Pathogenesis of haemophilic arthropathy (in eng). Haemophilia 12:117–121. 10.1111/j.1365-2516.2006.01268.x16684006
33. Hooiveld MJ Roosendaal G Van Den Berg H Bijlsma J Lafeber F Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study Rheumatology 2003 42 784 790 10.1093/rheumatology/keg220 12730540
Hooiveld MJ, Roosendaal G, Van Den Berg H, Bijlsma J, Lafeber F (2003) Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study. Rheumatology 42:784–79012730540
34. Øvlisen K Kristensen AT Jensen AL Tranholm M IL-1, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis Haemophilia 2009 15 802 810 10.1111/j.1365-2516.2008.01973.x 19444976
Øvlisen K, Kristensen AT, Jensen AL, Tranholm M (2009) IL-1, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia 15:802–810. 10.1111/j.1365-2516.2008.01973.x19444976
35. McInnes IB Schett G Cytokines in the pathogenesis of rheumatoid arthritis Nat Rev Immunol 2007 7 429 442 10.1038/nri2094 17525752
McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–44217525752
36. Iwamoto T Okamoto H Toyama Y Momohara S Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients FEBS J 2008 275 4448 4455 10.1111/j.1742-4658.2008.06580.x 18662305
Iwamoto T, Okamoto H, Toyama Y, Momohara S (2008) Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 275:4448–445518662305
37. Roosendaal V Lafeber B Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease Histopathology 1999 34 144 153 10.1046/j.1365-2559.1999.00608.x 10064394
Roosendaal V, Lafeber B (1999) Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 34:144–15310064394
38. Narkbunnam N Sun J Hu G Lin F-C Bateman TA Mihara M Monahan PE IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia J Thromb Haemost 2013 11 881 893 10.1111/jth.12176 23413986
Narkbunnam N, Sun J, Hu G, Lin F-C, Bateman TA, Mihara M, Monahan PE (2013) IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost 11:881–89323413986
39. Handa P Thomas S Morgan-Stevenson V Maliken BD Gochanour E Boukhar S Yeh MM Kowdley KV Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis J Leukoc Biol 2019 105 1015 1026 10.1002/JLB.3A0318-108R 30835899
Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, Yeh MM, Kowdley KV (2019) Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol 105:1015–102630835899
40. Zhou Y Que KT Zhang Z Yi ZJ Zhao PX You Y Gong JP Liu ZJ Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway Cancer Med 2018 7 4012 4022 10.1002/cam4.1670 29989329
Zhou Y, Que KT, Zhang Z, Yi ZJ, Zhao PX, You Y, Gong JP, Liu ZJ (2018) Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. Cancer Med 7:4012–4022. 10.1002/cam4.167029989329
41. Haxaire C Hakobyan N Pannellini T Carballo C McIlwain D Mak TW Rodeo S Acharya S Li D Szymonifka J Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway Blood J Am Soc Hematol 2018 132 1064 1074
Haxaire C, Hakobyan N, Pannellini T, Carballo C, McIlwain D, Mak TW, Rodeo S, Acharya S, Li D, Szymonifka J (2018) Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway. Blood J Am Soc Hematol 132:1064–1074
42. Irie K Uchiyama E Iwaso H Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee Knee 2003 10 93 96 10.1016/S0968-0160(02)00083-2 12649034
Irie K, Uchiyama E, Iwaso H (2003) Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 10:93–9612649034
43. Melchiorre D Morfini M Linari S Zignego AL Innocenti M Matucci Cerinic M Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis Rheumatology (Oxford) 2014 53 576 578 10.1093/rheumatology/ket280 24136067
Melchiorre D, Morfini M, Linari S, Zignego AL, Innocenti M, Matucci Cerinic M (2014) Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis. Rheumatology (Oxford) 53:576–578. 10.1093/rheumatology/ket28024136067
44. van Vulpen LF Schutgens RE Coeleveld K Alsema EC Roosendaal G Mastbergen SC Lafeber FP IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and is a potential target for therapy Blood J Am Soc Hematol 2015 126 2239 2246
van Vulpen LF, Schutgens RE, Coeleveld K, Alsema EC, Roosendaal G, Mastbergen SC, Lafeber FP (2015) IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and is a potential target for therapy. Blood J Am Soc Hematol 126:2239–2246
45. Kalluri R The biology and function of fibroblasts in cancer Nat Rev Cancer 2016 16 582 598 10.1038/nrc.2016.73 27550820
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16:582–598. 10.1038/nrc.2016.7327550820
46. Schonbeck U Mach F Libby P Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing J Immunol 1998 161 3340 3346 10.4049/jimmunol.161.7.3340 9759850
Schonbeck U, Mach F, Libby P (1998) Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 161:3340–33469759850
47. Jenkins G The role of proteases in transforming growth factor-β activation Int J Biochem Cell Biol 2008 40 1068 1078 10.1016/j.biocel.2007.11.026 18243766
Jenkins G (2008) The role of proteases in transforming growth factor-β activation. Int J Biochem Cell Biol 40:1068–107818243766
48. Hauw WW Chia JS Nandurkar HH Sashindranath M The potential role of protease systems in hemophilic arthropathy Blood Adv 2022 6 5505 5515 10.1182/bloodadvances.2022007028 35580335
Hauw WW, Chia JS, Nandurkar HH, Sashindranath M (2022) The potential role of protease systems in hemophilic arthropathy. Blood Adv 6:5505–551535580335
49. Peake NJ Khawaja K Myers A Jones D Cawston TE Rowan AD Foster HE Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study Rheumatology (Oxford) 2005 44 1383 1389 10.1093/rheumatology/kei025 16049050
Peake NJ, Khawaja K, Myers A, Jones D, Cawston TE, Rowan AD, Foster HE (2005) Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology (Oxford) 44:1383–1389. 10.1093/rheumatology/kei02516049050
50. Zheng L Luo D Li J Ye H Han Z Feng R Zhong Q Jing J Yao Y Pathological changes and expression of lysine oxidases and matrix metalloproteinases -1, -2, and -3 in ligaments of patients with haemophilic arthritis Haemophilia 2022 28 145 150 10.1111/hae.14443 34697874
Zheng L, Luo D, Li J, Ye H, Han Z, Feng R, Zhong Q, Jing J, Yao Y (2022) Pathological changes and expression of lysine oxidases and matrix metalloproteinases -1, -2, and -3 in ligaments of patients with haemophilic arthritis. Haemophilia 28:145–150. 10.1111/hae.1444334697874
51. Shiozawa K Yamane T Murata M Yoshihara R Tsumiyama K Imura S Shiozawa S MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy Arthritis Res Ther 2016 18 1 9 10.1186/s13075-016-0948-7 26732314
Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S, Shiozawa S (2016) MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Res Ther 18:1–926732314
52. Green M Gough A Devlin J Smith J Astin P Taylor D Emery P Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology 2003 42 83 88 10.1093/rheumatology/keg037 12509618
Green M, Gough A, Devlin J, Smith J, Astin P, Taylor D, Emery P (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42:83–8812509618
53. Yoshihara Y Nakamura H Ki O Yamada H Hayakawa T Fujikawa K Okada Y Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis Ann Rheum Dis 2000 59 455 461 10.1136/ard.59.6.455 10834863
Yoshihara Y, Nakamura H, Ki O, Yamada H, Hayakawa T, Fujikawa K, Okada Y (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455–46110834863
54. Lindy O Konttinen YT Sorsa T Ding Y Santavirta S Ceponis A López-otín C Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium Arthr Rheum: Off J Am Coll Rheumatol 1997 40 1391 1399 10.1002/art.1780400806
Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, López-otín C (1997) Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthr Rheum: Off J Am Coll Rheumatol 40:1391–1399
55. Sogi Y Yabe Y Hagiwara Y Tsuchiya M Onoda Y Sekiguchi T Itaya N Yoshida S Yano T Suzuki K Onoki T Itoi E Joint hemorrhage accelerates cartilage degeneration in a rat immobilized knee model BMC Musculoskelet Disord 2020 21 761 10.1186/s12891-020-03795-0 33213419
Sogi Y, Yabe Y, Hagiwara Y, Tsuchiya M, Onoda Y, Sekiguchi T, Itaya N, Yoshida S, Yano T, Suzuki K, Onoki T, Itoi E (2020) Joint hemorrhage accelerates cartilage degeneration in a rat immobilized knee model. BMC Musculoskelet Disord 21:761. 10.1186/s12891-020-03795-033213419
56. Sen D Chapla A Walter N Daniel V Srivastava A Jayandharan GR Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia (in eng) J Thromb Haemost 2013 11 293 306 10.1111/jth.12101 23231432
Sen D, Chapla A, Walter N, Daniel V, Srivastava A, Jayandharan GR (2013) Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia (in eng). J Thromb Haemost 11:293–306. 10.1111/jth.1210123231432
57. Matsuo K Owens JM Tonko M Elliott C Chambers TJ Wagner EF Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation Nat Genet 2000 24 184 187 10.1038/72855 10655067
Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF (2000) Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184–18710655067
58. Redlich K Hayer S Ricci R David J-P Tohidast-Akrad M Kollias G Steiner G Smolen JS Wagner EF Schett G Osteoclasts are essential for TNF-α–mediated joint destruction J Clin Investig 2002 110 1419 1427 10.1172/JCI0215582 12438440
Redlich K, Hayer S, Ricci R, David J-P, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G (2002) Osteoclasts are essential for TNF-α–mediated joint destruction. J Clin Investig 110:1419–142712438440
59. Hashizume M Hayakawa N Mihara M IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17 Rheumatology 2008 47 1635 1640 10.1093/rheumatology/ken363 18786965
Hashizume M, Hayakawa N, Mihara M (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology 47:1635–164018786965
60. Melchiorre D Milia AF Linari S Romano E Benelli G Manetti M Guiducci S Ceccarelli C Innocenti M Carulli C RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology J Rheumatol 2012 39 1678 1686 10.3899/jrheum.120370 22753650
Melchiorre D, Milia AF, Linari S, Romano E, Benelli G, Manetti M, Guiducci S, Ceccarelli C, Innocenti M, Carulli C (2012) RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology. J Rheumatol 39:1678–168622753650
61. Zhang S Lu C Ying J Wang P Xu T Chen D Jin H Tong P Inflammatory focal bone destruction in femoral heads with end-stage haemophilic arthropathy: a study on clinic samples with micro-CT and histological analyses Haemophilia 2015 21 e472 e478 10.1111/hae.12808 26388304
Zhang S, Lu C, Ying J, Wang P, Xu T, Chen D, Jin H, Tong P (2015) Inflammatory focal bone destruction in femoral heads with end-stage haemophilic arthropathy: a study on clinic samples with micro-CT and histological analyses. Haemophilia 21:e472–e478. 10.1111/hae.1280826388304
62. Adami G Fassio A Rossini M Caimmi C Giollo A Orsolini G Viapiana O Gatti D Osteoporosis in rheumatic diseases Int J Mol Sci 2019 10.3390/ijms20235867 31766755
Adami G, Fassio A, Rossini M, Caimmi C, Giollo A, Orsolini G, Viapiana O, Gatti D (2019) Osteoporosis in rheumatic diseases. Int J Mol Sci. 10.3390/ijms2023586731766755
63. Rodriguez-Merchan EC Osteoporosis in hemophilia: what is its importance in clinical practice? Expert Rev Hematol 2022 15 697 710 10.1080/17474086.2022.2108783 35912904
Rodriguez-Merchan EC (2022) Osteoporosis in hemophilia: what is its importance in clinical practice? Expert Rev Hematol 15:697–710. 10.1080/17474086.2022.210878335912904
64. Anagnostis P Vyzantiadis TA Charizopoulou M Adamidou F Karras S Goulis DG Karagiannis A Garipidou V Vakalopoulou S The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture Thromb Haemost 2013 110 257 263 10.1160/TH13-01-0030 23740140
Anagnostis P, Vyzantiadis TA, Charizopoulou M, Adamidou F, Karras S, Goulis DG, Karagiannis A, Garipidou V, Vakalopoulou S (2013) The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture. Thromb Haemost 110:257–263. 10.1160/TH13-01-003023740140
65. Takeuchi T Tanaka Y Ishiguro N Yamanaka H Yoneda T Ohira T Okubo N Genant HK van der Heijde D Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial Ann Rheum Dis 2016 75 983 990 10.1136/annrheumdis-2015-208052 26585988
Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983–990. 10.1136/annrheumdis-2015-20805226585988
